Ehrlichia-induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant

Angel A Mitma; Mary J Burgess; Frits van Rhee

doi:10.1111/tid.13621

Ehrlichia-induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant

Transpl Infect Dis. 2021 Aug;23(4):e13621. doi: 10.1111/tid.13621. Epub 2021 Apr 30.

Authors

Angel A Mitma¹, Mary J Burgess², Frits van Rhee³

Affiliations

¹ Department of Internal Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
² Department of Internal Medicine, Division of Infectious Diseases, UAMS, Little Rock, AR, USA.
³ The Myeloma Center, Division of Hematology/Oncology, UAMS, Little Rock, AR, USA.

PMID: 33877729
DOI: 10.1111/tid.13621

Abstract

Hemophagocytic lymphohistiocytosis (HLH) causes multiorgan failure due to the release of multiple cytokines mediating widespread inflammation. We present a patient with multiple myeloma on maintenance chemotherapy with the anti-CD38 monoclonal antibody daratumumab after autologous stem cell transplant (ASCT) who developed fatal HLH secondary to Ehrlichiosis.

Keywords: Ehrlichia; hemophagocytic lymphohistiocytosis (HLH); multiorgan failure; multiple myeloma; stem cell transplant.

Publication types

Case Reports

MeSH terms

Ehrlichia chaffeensis*
Ehrlichiosis* / drug therapy
Humans
Lymphohistiocytosis, Hemophagocytic* / etiology
Lymphohistiocytosis, Hemophagocytic* / therapy
Multiple Organ Failure / etiology
Stem Cell Transplantation / adverse effects